These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22457233)

  • 1. Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection.
    Li X; Priest RA; Woodward WJ; Tagge IJ; Siddiqui F; Huang W; Rooney WD; Beer TM; Garzotto MG; Springer CS
    Magn Reson Med; 2013 Jan; 69(1):171-8. PubMed ID: 22457233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.
    Huang W; Tudorica LA; Li X; Thakur SB; Chen Y; Morris EA; Tagge IJ; Korenblit ME; Rooney WD; Koutcher JA; Springer CS
    Radiology; 2011 Nov; 261(2):394-403. PubMed ID: 21828189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling.
    Li X; Cai Y; Moloney B; Chen Y; Huang W; Woods M; Coakley FV; Rooney WD; Garzotto MG; Springer CS
    J Magn Reson; 2016 Aug; 269():104-112. PubMed ID: 27288764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
    Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
    J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell membrane water exchange effects in prostate DCE-MRI.
    Li X; Priest RA; Woodward WJ; Siddiqui F; Beer TM; Garzotto MG; Rooney WD; Springer CS
    J Magn Reson; 2012 May; 218():77-85. PubMed ID: 22578558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.
    Huang W; Li X; Morris EA; Tudorica LA; Seshan VE; Rooney WD; Tagge I; Wang Y; Xu J; Springer CS
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17943-8. PubMed ID: 19004780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shutter-speed dynamic contrast-enhanced MRI: Is it fit for purpose?
    Buckley DL
    Magn Reson Med; 2019 Feb; 81(2):976-988. PubMed ID: 30230007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology.
    Yankeelov TE; Rooney WD; Huang W; Dyke JP; Li X; Tudorica A; Lee JH; Koutcher JA; Springer CS
    NMR Biomed; 2005 May; 18(3):173-85. PubMed ID: 15578708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
    Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
    AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular-interstitial water exchange and its effect on the determination of contrast agent concentration in vivo: dynamic contrast-enhanced MRI of human internal obturator muscle.
    Buckley DL; Kershaw LE; Stanisz GJ
    Magn Reson Med; 2008 Nov; 60(5):1011-9. PubMed ID: 18956419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging.
    Fusco R; Sansone M; Petrillo M; Setola SV; Granata V; Botti G; Perdonà S; Borzillo V; Muto P; Petrillo A
    Magn Reson Imaging; 2016 Sep; 34(7):839-45. PubMed ID: 27071309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer.
    Cai W; Li F; Wang J; Du H; Wang X; Zhang J; Fang J; Jiang X
    NMR Biomed; 2014 Jul; 27(7):817-25. PubMed ID: 24809332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate.
    Alonzi R; Taylor NJ; Stirling JJ; d'Arcy JA; Collins DJ; Saunders MI; Hoskin PJ; Padhani AR
    J Magn Reson Imaging; 2010 Jul; 32(1):155-64. PubMed ID: 20578023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer.
    Li X; Welch EB; Chakravarthy AB; Xu L; Arlinghaus LR; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Abramson VG; Grau AM; Gore JC; Yankeelov TE
    Magn Reson Med; 2012 Jul; 68(1):261-71. PubMed ID: 22127821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T.
    Kim J; Moestue SA; Bathen TF; Kim E
    Tomography; 2019 Sep; 5(3):308-319. PubMed ID: 31572792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
    Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
    Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of quantitative pharmacokinetic parameters and relative quantitative pharmacokinetic parameters in breast lesions with dynamic contrast-enhanced MRI].
    Sun TT; Liu WH; Zhang YQ; Li LH; Wang R; Ye YY
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(29):2266-2270. PubMed ID: 28780840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.